ELI LILLY & CO (LLY.DE) Stock Price, Quote, News and Overview
FRA:LLY - Deutsche Boerse Ag - US5324571083 - Common Stock - Currency: EUR
LLY.DE Quote, Performance and Key Statistics
ELI LILLY & CO
FRA:LLY (2/5/2025, 12:31:45 PM)
805
+23.8 (+3.05%)
The current stock price of LLY.DE is 805 EUR. In the past month the price increased by 4.83%. In the past year, price increased by 13.79%.
LLY.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 79.43 | 741.99B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.22 | 413.69B | ||
| NOV.DE | NOVO NORDISK A/S-B | 28.97 | 365.29B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.25 | 355.12B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SAN.PA | SANOFI | 14.6 | 257.71B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.1 | 220.08B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B | ||
| PFE.DE | PFIZER INC | 9.99 | 141.50B |
Related stock screener links
About LLY.DE
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. The company is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 43000
Company Website: https://www.lilly.com/
Investor Relations: https://investor.lilly.com/
Phone: 13172762000
LLY.DE FAQ
What is the stock price of LLY.DE?
The current stock price of LLY.DE is 805 EUR.
What is the symbol for ELI LILLY & CO stock?
The exchange symbol of ELI LILLY & CO is LLY and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is LLY.DE stock listed?
LLY.DE stock is listed on the Deutsche Boerse Ag exchange.
Is LLY.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for LLY.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of LLY.DE.
Does LLY.DE stock pay dividends?
LLY.DE has a dividend yield of 0.73%. The yearly dividend amount is currently 4.28.
When does LLY.DE stock report earnings?
LLY.DE will report earnings on 2025-02-06, before the market open.
What is the Price/Earnings (PE) ratio of LLY.DE?
The PE ratio for LLY.DE is 81.81. This is based on the reported non-GAAP earnings per share of 9.84 and the current share price of 805 EUR.
LLY.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LLY.DE. When comparing the yearly performance of all stocks, LLY.DE turns out to be only a medium performer in the overall market: it outperformed 53.88% of all stocks.
LLY.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LLY.DE. While LLY.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
LLY.DE Financial Highlights
Over the last trailing twelve months LLY.DE reported a non-GAAP Earnings per Share(EPS) of 9.84. The EPS increased by 71.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.48% | ||
| ROA | 11.07% | ||
| ROE | 58.78% | ||
| Debt/Equity | 2.04 |
LLY.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to LLY.DE. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 109.18% and a revenue growth 34.67% for LLY.DE